Pluri Gets $4.2M Contract To Advance Development Of Treatment For Radiation Syndrome
Portfolio Pulse from Nabaparna Bhattacharya
Pluri Inc. (NASDAQ:PLUR) has signed a $4.2 million contract with the U.S. National Institute of Allergy and Infectious Diseases to advance the development of its PLX-R18 cell therapy for Hematopoietic Acute Radiation Syndrome (H-ARS). The contract supports Pluri's goal to achieve marketing approval for PLX-R18 with the U.S. Food and Drug Administration (FDA). PLUR shares are trading higher by 7.6% in the premarket session.
July 11, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pluri's new contract to advance the development of its PLX-R18 cell therapy could potentially boost its stock price.
The news of Pluri's contract with the U.S. National Institute of Allergy and Infectious Diseases is directly related to the company and its stock. The contract, worth $4.2 million, is for the development of Pluri's PLX-R18 cell therapy, a potential treatment for H-ARS. This could potentially increase the company's revenues and profitability, which could in turn boost its stock price. The fact that PLUR shares are already trading higher in the premarket session indicates that the market has reacted positively to this news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100